How To Reduce Batch Loss In Biopharma Production

Batch failures in biopharmaceutical manufacturing remain a costly challenge despite gradual improvements in recent years. Industry surveys show that failures occur roughly every 64 weeks, with 2022 averaging 58 weeks between incidents. While the underlying causes are consistent, the top contributors often vary by facility size and change over time. For manufacturers, equipment selection and supplier expertise play a critical role in reducing risk, both during clinical development and at commercial scale. Understanding the most common failure points in downstream purification and implementing strategies to evaluate suppliers and processes can help safeguard production.

Explore key insights into why failures happen and practical steps to minimize their impact.